FedEx is chasing the GLP-1 boom. Why healthcare logistics means big business
HS 27/07/2026
The boom in GLP-1 weight-loss drugs and other specialized medicines has created lucrative logistics opportunities in an industry that pays a premium for reliability, visibility, and regulatory know-how. The expertise needed to properly transport these temperature-sensitive therapies is just part of the reason why FedEx created a dedicated unit to handle what has become a $10 billion-per-year business, representing more than 10% of annual revenue. Earlier this month, the company launched FedEx Life Sciences, building on years of healthcare delivery investments to ensure controlled environments, fast transportation, and constant end-to-end monitoring from manufacturing facilities and warehouses to labs, pharmacies, and patients. The announcement marks FedEx’s latest move to bolster business-to-business healthcare shipping, one of the four B2B verticals the company has prioritized. Automotive, aerospace, and data centers are the other three. Management believes that increasing revenue from these crucial industries can drive faster growth, stronger margins, and steadier demand less dependent on the ups and downs of consumer spending. Healthcare and life sciences is a “great growing market for FedEx to attack,” Chief Customer Officer Brie Carere told CNBC. She described Club name FedEx as “incredibly well positioned,” given the company’s buildout of premium supply chain monitoring technology and so-called cold chain corridors — the air and ground capabilities necessary to ensure safe end-to-end transport of drugs, biologics, and clinical trial materials. Biologics are treatments, such as vaccines and gene therapies, made from living organisms. “There is an inherent value and higher price with that security, compliance, [and] temperature regulation,” Carere said. The goal isn’t to just charge a premium for transporting sensitive medicines, she said, but also to help drug companies lower overall costs by reducing product loss and preventing compliance issues, which ultimately reduces waste and their cost to serve. Carere said that healthcare shipping represents an $80 billion market opportunity growing at a 7% compound annual growth rate (CAGR) over the next six years. Some of the hottest segments are growing even faster, including GLP-1s — such as Eli Lilly ‘s Mounjaro for diabetes and Zepbound for obesity — at roughly 20%, and cell and gene therapies at about 25%. There is an inherent value and higher price with that security, compliance, temperature regulation. FedEx Chief Customer Officer Brie Carere FedEx is hardly alone in chasing the growing healthcare and life sciences logistics market. Last month, United Parcel Service (UPS) announced a $48 million expansion of its temperature-controlled healthcare network, adding specialized facilities across Europe, Asia, and the Americas. “Both are kind of playing in their own lanes a bit and not necessarily competing head on for the same type of business,” Deutsche Bank analyst Richa Harnain said. UPS said its healthcare business generated $11.2 billion in revenue in 2025. Another industry player is global healthcare services provider Cardinal Health , which does some of the same logistics and transport of drugs and medical supplies as part of its business. FedEx said Cardinal, also a Club name, is a customer as well as a strategic collaborator. The two forged a partnership back in 2013 to give joint customers access to dozens of warehouses and distribution centers across the U.S. Industry experts say the renewed focus on these types of sleepy businesses isn’t a coincidence. With an aging population, the rise of biologics and personalized medicine has “grown exponentially within the last couple years,” leading to the transformation of healthcare supply chains, said Lora Cecere, founder of Supply Chain Insights. “The need for cold chain reliability has grown as science becomes better, and the supply chains have become more complicated for special handling of drugs,” she told CNBC in an interview. Cecere said healthcare logistics is “a richer supply chain, in terms of profit and margin opportunity.” She said that “pharma has the ability to pay” because the sector’s profit margins are the highest of any major manufacturing industry. The high value of biologics and other specialty medicines means the cost of a failed shipment can far outweigh the cost of premium transportation, she explained. While FedEx is widely known for business-to-consumer (B2C) shipments — think your online shopping order arriving at your door — the company has been leaning harder into those more profitable B2B shipments. These higher-margin verticals are housed in the company’s largest segment, FedEx Express, which accounted for roughly 86% of total revenue during the company’s fiscal 2026 fourth quarter , which ended May 31 and was reported in late June. Another nearly 10% of fiscal Q4 revenue came from FedEx Freight , which was spun off into a separate, publicly traded company on June 1. It will not be included in results going forward. While FedEx doesn’t provide a clean revenue split of B2C versus B2B by segment, CEO Raj Subramanian said during the company’s fiscal 2026 third-quarter earnings call back in March: “Nearly half of our revenue growth [was] driven by B2B services, an important enabler of increased profitability.” A narrower focus on these specialized B2B segments is now a core part of how the company plans to make more money. At its investor day in February, FedEx said it plans to hit $98 billion in revenue by 2029 through premium B2B and B2C volumes. After the FDXF spin-off, FedEx puts current annual revenue at around $86 billion. The need for cold chain reliability has grown as science becomes better, and the supply chains have become more complicated. Supply Chain Insights founder Lora Cecere While the company has always had sales and marketing dedicated to healthcare, FedEx’s Carere said the launch of FedEx Life Sciences brings together that operation and the engineering and quality teams under one organization built specifically around pharmaceutical customers. Rather than creating a separate network, FedEx is layering specialized expertise onto its existing global transportation system to better handle patient-critical shipments. “We’re building out a team that will ensure that healthcare packages — and the patient behind the package — are the utmost priority among the 18 million packages that we flow every day,” Carere said. “We’re really focused on being the industrial network of the world.” She said cold-storage capacity is being added to hubs around the world — focusing on major pharmaceutical trade lanes rather than building everywhere indiscriminately. In its global base of Memphis, Tennessee, FedEx has for years had a dedicated healthcare warehouse, featuring storage areas at five different temperature ranges. That includes a freezer at minus 150 degrees Celsius, equal to minus 238 degrees Fahrenheit — colder than the average temperature of Saturn, a planet 793 million miles further away from the sun than Earth. FedEx believes it can manage nearly every stage of a pharmaceutical shipment under one roof — from global air freight and small parcel delivery to customs clearance and quality control. As healthcare companies diversify manufacturing across multiple countries, Carere said global reach becomes that much more important. She also stressed custodial control as a core differentiator in healthcare logistics, saying the fewer handoffs and more control FedEx has over sensitive shipments from origin to destination, the lower the risk of something going wrong. “FedEx can go to market with a really streamlined bundle,” she added, noting how the carrier can move through major pharmaceutical trade lanes including parcel delivery, global air freight and customs clearance. FDX YTD mountain FedEx YTD FedEx’s technology is another competitive advantage, according to Carere, who is also co-CEO of FedEx Services, which provides technological support to the company’s operating units. She said that about 40% of healthcare customers already use FedEx Surround, a real-time shipment-tracking platform that uses machine learning to anticipate disruptions before they occur. “The ability for predictive analytics through AI is a great opportunity,” according to Cecere of Supply Chain Insights, “to be able to do safe and secure delivery.” This is important for healthcare companies because if a delay threatens a temperature-sensitive shipment, the package can be rerouted or returned to the sender before the medicine is compromised. FedEx has another real-time tracking tool called SenseAware for shipments that need more advanced tracking, higher security, and quality assurance. Those two tools are the kind of tech that “healthcare customers in particular appreciate for FedEx,” Deutsche Bank’s Harnain said. For its part, UPS offers a tracking and management tool called Quantum View that offers visibility and control for small package shipments. Bottom line FedEx becoming more deliberate about higher-margin healthcare shipments is one of the core reasons why we see upside to its business growth. We believe FedEx’s premium services command a greater value. The company still has to prove that its investments in healthcare can translate to sustained market share gains and further improve the company’s growth profile. During last week’s July Monthly Meeting , Jim Cramer was bullish on FedEx and FedEx Freight, saying that, as standalone companies, they will be able to focus on what makes sense for their different businesses. We bought more shares of each company on July 1. On a spin-adjusted basis, FedEx stock has gained 35% year to date. FedEx Freight has been volatile since its debut, but that isn’t unusual for spinoffs early on while the stock finds a dedicated investor base. We bought some more FDXF on Friday, thinking the selling has been overdone . (Jim Cramer’s Charitable Trust is long FDX, FDXF, CAH. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
